The Vienna biotech company Marinomed Biotech AG announced the successful private placement of a convertible bond (AT000A1WD52) on the Third Market (MTF) on the Vienna Stock Exchange today. With the support of the issuing bank Erste Group, a total volume of 7 million euro was placed with institutional and private investors. The convertible bond is scheduled to mature in 2021 and Marinomed will pay a coupon of 4 percent. In the event of a public offering, the investors will have the right to convert the bond to shares.
About Marinomed Biotech AG (status as of July 2017) Marinomed Biotech AG is a biopharmaceutical company based in Vienna. The company’s already marketed products are used in the treatment of colds and flu-like infections based on the MAVIREX® platform. The products are sold through international partners in more than 35 countries throughout the world. The company has developed additional products for use in the treatment of allergies and autoimmune diseases based on the patent-pending MARINOSOLV® platform. Marinomed Biotechnologie GmbH was founded in 2006 as a spin-off of the University of Veterinary Medicine, Vienna.
Further information can be found at www.marinomed.com.
Contact Dr. Eva Prieschl-Grassauer Marinomed Chief Scientific Officer Tel: +43 (0)1 250 77 - 4460 Email: email@example.com
PR&D – Public Relations für Forschung & Bildung Tel: +43 (0) 1 505 70 44 Email: firstname.lastname@example.org